Why do iron, thyroid, and vitamin D deficiencies compound?

How it works

Vitamin D-thyroid autoimmunity (mixed evidence): vitamin D regulates immune function via VDR signalling on T-regulatory cells. Vitamin D deficiency is associated with Hashimoto thyroiditis in observational studies. RCT evidence on vitamin D supplementation reducing TPO antibody levels is genuinely mixed. Iron-vitamin D (modest mechanistic link): the renal 1-alpha-hydroxylase enzyme (CYP27B1) that activates 25-hydroxyvitamin D is a haem-containing cytochrome P450, so severe iron deficiency could theoretically impair vitamin D activation. Magnesium is the better-anchored cofactor for this pathway in published literature (Uwitonze and Razzaque 2018 J Am Osteopath Assoc 118(3):181-189, PMID 29480918). Population studies show low vitamin D and low ferritin co-occur in premenopausal women, but shared dietary or lifestyle factors are more plausible at the population level than direct iron-on-vitamin-D-activation effect.

Safety profile

Self-supplementation with iron without confirmed deficiency can be harmful, particularly in haemochromatosis or other iron-loading conditions. Where Hashimoto thyroiditis with hypothyroidism is established, levothyroxine replacement is first-line and not optional. The 2024 Endocrine Society update (Demay 2024 JCEM 109(8):1907-1947, PMID 38828931) does not specifically endorse vitamin D supplementation for autoimmune thyroid disease beyond general adequacy.

Special populations

Hypothyroid populations: iron-thyroid bidirectional axis means iron-deficient hypothyroid patients warrant attention to both. Hashimoto thyroiditis: iron deficiency appears more prevalent (Garofalo 2023). Vegetarians and vegans: higher risk for both iron and B12 deficiency, plus latitude-dependent vitamin D status. Older adults: vitamin D deficiency is common; iron deficiency requires GI workup per BSG 2021 to exclude malignancy.

Interactions

Standard iron interactions: calcium, polyphenols, antacids, and PPIs reduce iron absorption when concurrent. Vitamin D coadministration with iron does not have a documented absorption interaction. Selenium has been studied for autoimmune thyroid disease (Huwiler 2024 systematic review and meta-analysis, Thyroid) but evidence for routine selenium supplementation as part of combined iron-thyroid-vitamin-D approach is limited.

Guideline positions

Hess 2002 (J Nutr 132(7):1951-1955, PMID 12097675) is the foundational mechanistic study for iron-thyroid in rats. Garofalo 2023 (Nutrients 15(22):4790, PMID 38004184) systematic review synthesises the iron-thyroid evidence in humans. Campbell 1992 (Ann Intern Med 117(12):1010-1013, PMID 1443969) is the foundational levothyroxine-iron interaction study. Demay 2024 (JCEM 109(8):1907-1947, PMID 38828931) Endocrine Society vitamin D update covers vitamin D adequacy and deficiency. Uwitonze and Razzaque 2018 (J Am Osteopath Assoc 118(3):181-189, PMID 29480918) anchors the magnesium-vitamin D activation pathway.

Practical framework

Sequencing is individualised. Where iron deficiency is severe (Hb low or ferritin below 30 with symptoms), iron correction first is reasonable because iron repletion can improve thyroid lab abnormalities. Where vitamin D is severely deficient (below 25 nmol/L) and bone or muscle symptoms are prominent, vitamin D loading first is reasonable. Where Hashimoto thyroiditis with hypothyroidism is established, levothyroxine replacement is first-line. The clinical implication: investigate all three when fatigue or cognitive symptoms are persistent, and address each through its own evidence-based pathway. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: iron correction first is the universal sequencing rule. Sequencing is genuinely individualised; what gets corrected first depends on which is most deficient by lab values, which symptoms are most prominent, and what medications are involved.

Claim: vitamin D supplementation reliably reduces Hashimoto TPO antibodies. The RCT evidence on this specific outcome is mixed; some trials show modest reductions at 3-6 months on doses of 25-50 mcg/day, others show no significant effect. The 2024 Endocrine Society update does not endorse vitamin D supplementation for autoimmune thyroid disease beyond general adequacy.

Claim: iron-on-vitamin-D-activation is the dominant mechanism for low ferritin and low vitamin D co-occurrence. Shared dietary, lifestyle, and menstrual loss factors are more plausible at the population level.